BridgeBio Pharma, Inc. BBIO
65.57
(0.71)
(1.07%)
as of 25 Sep
- Market cap
- $13.1B
- P/E
- 0.0×
Follow BBIO
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
20.45 | 24.94 | 29.18 | 28.17 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(205.09) | (73.32) | (259.66) | (90.94) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
22.15 | 26.65 | 31.71 | 31.58 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(36.36) | (34.81) | (35.70) | (19.11) | |
EV/FCF |
(35.58) | (34.07) | (34.94) | (18.69) | |
Quick Ratio |
1.09 | 1.40 | 2.52 | 3.52 | |
Current Ratio |
1.23 | 1.52 | 2.77 | 3.88 | |
Net Debt/EBITDA |
(11.60) | (9.58) | (9.57) | (8.21) | |
Debt/Assets |
158.35% | 140.49% | 197.91% | 185.43% | |
Debt/Equity |
(0.77) | (0.85) | (0.89) | (0.96) | |
Asset Turnover |
0.62 | 0.51 | 0.54 | 0.43 | |
Operating CF/Net income |
0.47 | 1.20 | 0.29 | 0.60 | |
Capex/Depreciation |
(0.15) | (0.02) | 0.00 | 1.73 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
61.33% | 65.10% | 75.51% | 93.52% | |
Selling, General and Administrative Expense of Revenue |
76.44% | 84.26% | 102.53% | 114.02% | |
Intangible Assets out of Total Assets |
0.02 | 0.02 | 0.03 | 0.03 | |
Share Based Compensation of Revenue |
18.09% | 17.09% | 22.47% | 29.21% | |
Graham Net Nets |
(0.18) | (0.17) | (0.15) | (0.21) | |
Graham Number |
32.06 | 31.30 | 30.36 | 30.70 | |
Earnings Yield |
(4.79%) | (5.04%) | (4.94%) | (8.05%) | |
Free Cash Flow Yield |
(3.04%) | (3.14%) | (3.11%) | (6.00%) | |
Revenue per Share |
1.24 | 1.00 | 0.81 | 0.63 | |
Operating CF per Share |
(0.36) | (1.01) | (0.29) | (0.57) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.01) | |
Free Cash Flow per Share |
(0.37) | (1.01) | (0.29) | (0.59) | |
Cash per Share |
3.68 | 4.83 | 3.07 | 3.37 | |
Shareholders Equity per Share |
(12.79) | (11.64) | (10.84) | (10.02) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(12.79) | (11.64) | (10.84) | (10.02) | |
Free Cash Flow |
(71.54) | (197.35) | (56.45) | (112.44) | |
Working Capital |
202.49 | 424.93 | 509.78 | 622.78 | |
Capital Expenditures |
(0.44) | (0.07) | (0.03) | (2.87) | |
Net Current Asset Value |
(2,629.04) | (2,397.60) | (2,214.29) | (2,081.62) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.02 | |
Net Profit Margin |
(62.47%) | (84.33%) | (125.09%) | (151.40%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
165.68 | 160.25 | 72.08 | 58.50 | |
Average Payables |
26.67 | 28.29 | 22.92 | 16.03 | |
Average Inventory |
35.56 | 18.47 | — | — | |
Average Assets |
1,148.74 | 1,126.31 | 927.68 | 831.61 | |
Average Common Equity |
(2,141.42) | (1,953.18) | (1,766.88) | (1,570.89) |
Columns are period end dates